Myrtle Beach, SOUTH%20CAROLINA5 Active Studies

Bladder Cancer Clinical Trials in Myrtle Beach, SOUTH%20CAROLINA

Find 5 actively recruiting bladder cancer clinical trials in Myrtle Beach, SOUTH%20CAROLINA. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
425
Enrolling

Recruiting Bladder Cancer Studies in Myrtle Beach

RecruitingMyrtle Beach, SOUTH%20CAROLINANCT03945162

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with NMIBC CIS (with or without resected papillary disease (Ta, T1)) that are conside...

125 participants
Theralase® Technologies Inc.
View Study Details
RecruitingMyrtle Beach, SOUTH%20CAROLINANCT06331299

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

This Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle inv...

92 participants
UroGen Pharma Ltd.
View Study Details
RecruitingMyrtle Beach, SOUTH%20CAROLINANCT06995677

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC...

90 participants
Tyra Biosciences, Inc
View Study Details
RecruitingMyrtle Beach, SOUTH%20CAROLINANCT05710848

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients wit...

75 participants
SURGE Therapeutics
View Study Details
RecruitingMyrtle Beach, SOUTH%20CAROLINANCT03914794

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with ...

43 participants
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View Study Details

About Bladder Cancer Clinical Trials in Myrtle Beach

Bladder cancer occurs in the tissues of the bladder and is one of the most common cancers. It has a high recurrence rate, requiring ongoing monitoring. Treatments include surgery, intravesical therapy, chemotherapy, and immunotherapy.

There are currently 5 bladder cancer clinical trials recruiting participants in Myrtle Beach, SOUTH%20CAROLINA. These studies are seeking a combined 425 participants. Research is being sponsored by Theralase® Technologies Inc., UroGen Pharma Ltd., Tyra Biosciences, Inc and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Bladder Cancer Clinical Trials in Myrtle Beach — FAQ

Are there bladder cancer clinical trials in Myrtle Beach?

Yes, there are 5 bladder cancer clinical trials currently recruiting in Myrtle Beach, SOUTH%20CAROLINA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Myrtle Beach?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Myrtle Beach research site will contact you about next steps.

Are clinical trials in Myrtle Beach free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Myrtle Beach studies also compensate for your time and travel.

What bladder cancer treatments are being tested?

The 5 active trials in Myrtle Beach are testing new therapies including novel drugs, biologics, and treatment approaches for bladder cancer.

Data updated March 2, 2026 from ClinicalTrials.gov